Allopurinol has little benefit in cardiac syndrome X

Allopurinol has little benefit in cardiac syndrome X

(HealthDay)—Allopurinol does not appear to improve exercise capacity or peripheral endothelial or coronary function in patients with cardiac syndrome X, according to a study published online Oct. 28 in Cardiovascular Therapeutics.

Tiong Keng Lim, M.D., from National Heart Centre Singapore, and colleagues randomized 19 patients with cardiac syndrome X (mean age 59 years) to six weeks of treatment with either allopurinol (600mg/day) or placebo. Patients were crossed over to the other study arm after a four-week washout period.

The researchers found that allopurinol significantly reduced serum uric acid levels versus placebo. There was no significant difference in maximum exercise time, coronary flow reserve, or flow-mediated vasodilatation of the between the allopurinol and placebo groups. However, there was a trend toward allopurinol reducing serum B-type natriuretic peptide compared with placebo (P = 0.07).

"In patients with cardiac syndrome X, high dose allopurinol did not improve , coronary or peripheral endothelial function," conclude the authors.

Explore further

Allopurinol does not increase chronic kidney disease risk in gout patients

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Allopurinol has little benefit in cardiac syndrome X (2017, November 19) retrieved 27 February 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments